Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Adverse drug reactions of GLP-1 agonists: a systematic review of case reports
R Shetty, FT Basheer, PG Poojari, G Thunga… - Diabetes & Metabolic …, 2022 - Elsevier
Background and aim The importance of glucagon-like peptide-1 (GLP-1) agonists is
increasing because of its blood sugar controlling and weight loss properties. The data …
increasing because of its blood sugar controlling and weight loss properties. The data …
Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature
CE Salazar, MK Patil, O Aihie, N Cruz… - Archives of …, 2024 - Springer
Abstract Glucagon-like-peptide-1 (GLP-1) agonists are an emerging class of medications
used to manage type 2 diabetes mellitus (T2DM) and weight loss, with demonstrated …
used to manage type 2 diabetes mellitus (T2DM) and weight loss, with demonstrated …
Hypersensitivity to glucagon‐like peptide‐1 receptor agonists: A case of delayed urticaria‐like rash to dulaglutide and literature review
L Bianchi, S Ali Biglu Marash, N Malatesta… - JEADV Clinical …, 2024 - Wiley Online Library
Dulaglutide is a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, which stimulates insulin
release via activation of GLP‐1 receptors on pancreatic beta cells. We report the case of a …
release via activation of GLP‐1 receptors on pancreatic beta cells. We report the case of a …
Side effects of insulin and oral antihyperglycemic drugs
Abstract Side Effects of Drugs Annual is an annual publication that publishes side effects,
adverse reactions and toxicities associated with medications. The series supplements the …
adverse reactions and toxicities associated with medications. The series supplements the …
A Decadal Exploration of Cutaneous Adverse Effects of FDA-Approved Cardiovascular Medications: Insights from 2013 to 2023
A Jallorina, K Vij, L Wan, J Thomas… - Journal of …, 2022 - journals.lww.com
Given the high prevalence of cardiovascular disease in the United States, there is a critical
need for new medications to improve outcomes of these diseases. The US Food and Drug …
need for new medications to improve outcomes of these diseases. The US Food and Drug …